AGRX - Agile Therapeutics GAAP EPS of -$2.71 beats by $0.99 revenue of $2.1M beats by $0.12M
- Agile Therapeutics press release ( NASDAQ: AGRX ): Q2 GAAP EPS of -$2.71 beats by $0.99 .
- Revenue of $2.1M (+75.0% Y/Y) beats by $0.12M .
- “Our goals as a company are to grow our Twirla brand and become cash flow positive. We believe we took important steps towards achieving these goals in the second quarter by once again increasing Twirla demand and revenue while significantly decreasing our operating expenses,” said Agile Therapeutics Chairman and Chief Executive Officer Al Altomari. “We plan to drive further growth in the second half of 2022 by executing on previously disclosed components of our business plan like the Afaxys partnership and connected TV campaign, while also exploring and implementing new initiatives like the product supply agreement we are announcing with Nurx, Thirty Madison’s Reproductive Health Brand.”
For further details see:
Agile Therapeutics GAAP EPS of -$2.71 beats by $0.99, revenue of $2.1M beats by $0.12M